Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma

Bruce E. Hillner, Deborah Schrag, Daniel J. Sargent, Charles S. Fuchs, Richard M. Goldberg

Research output: Contribution to journal › Article › peer-review

32 Scopus citations

Fingerprint

Dive into the research topics of 'Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma'. Together they form a unique fingerprint.

Medicine & Life Sciences